August 20 – 21, 2019

The industry definitive IPF forum built from research with drug developers for drug developers is your opportunity to benchmark and advance not just your own pipeline; but the pre-competitive IPF landscape.

Join the leading minds from biopharma and academia across three days of unrivalled, scientifically driven and case-study based analysis and discussion, as together they close the translational gap between preclinical predictability and clinical attrition.

Last year, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging, share clinical insights, and evaluate better recapitulating disease physiology in vitro exclusively for IPF.  The 3rd IPF Summit 2019 will build on this to:

  • Look beyond bleomycin to more confidently and robustly utilize preclinical models
  • Take advantage of human genetics to understand differences in the IPF population and advance the enrichment of clinical trial patient selection
  • Outline phase II successes to debate the design appropriate phase III trials and combination therapy decisions

Be part of the definitive IPF Summit dedicated to solving the translational challenges hindering the development of truly curative IPF therapeutics

“All the speakers were superb, and every session provided novel and important insight regarding IPF. Great job!”

- Ceders-Sinai, IPF Summit 2017 Attendee

“This disease specific conference was informative, by planning a concentrated topic it gave an opportunity to look through a tighter lens”

- Genentech, IPF Summit 2017 Attendee





Media Partner